source
- GSK receives FDA accelerated approval for neladalkib (Nelkarmi) in ALK-positive lung cancer, second win from Nuvalent dealGSK announced that the FDA has granted accelerated approval to its tyrosine kinase inhibitor neladalkib, to be sold under the brand name Nelkarmi, for patients with ALK‑positive non‑small cell lung…
- J&J buys Ollin Biosciences for $2.2 billion, taps Blackstone for $750 million Phase 3 eye drug fundingJohnson & Johnson announced it will acquire Texas‑based ophthalmology biotech Ollin Biosciences, paying $2.2 billion upfront for the company and its late‑stage bispecific antibody targeting retinal…